| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Quest Diagnostics said on Wednesday it would acquire Canada-based LifeLabs from pension plan owner OMERS for about C$1.35 billion, or about $985 million, including net debt. LifeLabs, which provides community laboratory tests, would retain its brand, Canadian headquarters and management after the acquisition is closed. The U.S. laboratory operator will acquire 100% of the equity of LifeLabs and expects to fund the acquisition through cash on hand and debt. Quest expects the deal to generate roughly $710 million in annual revenues.
Quest Diagnostics plans to acquire Allina Health's laboratory assets at most of its ambulatory clinic sites. The company and the Minneapolis-based health system have signed an definitive agreement and expect the transaction to close this fall, pending regulatory approvals. Financial terms were not disclosed.
If it feels like you’ve been hearing more about testosterone lately, you’re not wrong. However, the question of whether or not you should get your own testosterone checked isn’t so straightforward. To put it simply, if you’re not experiencing persistent symptoms associated with low testosterone, you have no reason to get your levels checked—regardless of what they might be. “If you're otherwise feeling well, I really don't advocate just going on a fishing expedition,” says Sanjay B. Dixit, MD, medical director of cardiometabolic endocrine and wellness clinical solutions at Quest Diagnostics. “That's actually one of the key points in the Endocrine Society’s guidelines from 2018, that they do not recommend testing in otherwise asymptomatic men.”
Despite the national hepatitis C elimination goals for 2030 to achieve at least 80% of persons with hepatitis C to achieve viral clearance, the goals across states is consistently falling under. In fact, analysis of data collected during 2013–2022 from a national laboratory found that HCV clearance or cure proportions among persons with virus by state was between 10% to 51%.1This data was published in the Centers for Disease Control’ and Prevention's (CDC) MMWR late last week. The investigators collected 10 years of data from January 1, 2013 through December 31, 2022 utilizing information from the national laboratory company, Quest Diagnostics. They analyzed patients from all 50 states and the District of Columbia.
A blood test could help reduce costs for health plans by reliably identifying patients who might be able to safely forgo chemotherapy after surgery for stage II colorectal cancer, according to a study published in JAMA Health Forum, a member of the JAMA Network. Researchers from Haystack Oncology, a Quest Diagnostics company and developer of the Haystack MRD tumor-informed ctDNA MRD technology, City of Hope and the Walter and Eliza Hall Institute of Medical Research conducted the study. In June 2022, a randomized clinical trial (DYNAMIC) demonstrated that a tumor-informed ctDNA MRD test performed on patients with stage II colorectal cancer reduced the application of adjuvant chemotherapy (ACT) by nearly half (15% vs. 28%) without compromising recurrence-free survival.
Workers are cheating on drug tests at the highest rate in more than 30 years, according to one of the U.S.’s largest drug-testing labs. The increase in tampered tests came from samples collected in 2023. About 31,000 drug screens out of 5.5 million showed signs of cheating, according to Quest Diagnostics. “Some American workers are going to great lengths to attempt to subvert the drug-testing process,” said Dr. Suhash Harwani, senior director of science for workforce health solutions at Quest. The percentage of urine samples that came back positive for drugs among the U.S. workforce remained steady at a two-decade high for the third year in a row. But the substantial rise of tampering, as well as the patchwork of new marijuana laws across the U.S., have intensified challenges for employers seeking to keep drugs out of the workplace.
Quest Diagnostics is building out its artificial intelligence-powered cancer pathology offerings through a multi-layered deal with PathAI—acquiring some assets, licensing out others. The testing giant will be buying out PathAI’s Memphis, Tennessee-based diagnostics laboratory, with plans to turn it into its own AI and digital R&D solutions center to help support its current AmeriPath and Dermpath Diagnostics pathology businesses.
Quest Diagnostics suggested Tuesday that laboratory industry staffing shortages could redound to its benefit as hospital labs are forced to either scale back or sell off their lab operations. On a conference call following the release of the company's Q1 2024 earnings results, Quest Chairman, President, and CEO Jim Davis observed that the company has seen particular strength in hospital reference testing as that portion of its business continued to grow at a faster rate than it had prior to the COVID-19 pandemic. He said that this trend was driven in part by the lab business's much discussed workforce crunch, noting that hospitals "face persistent challenges with staffing certain roles in specialized fields like histology, microbiology, and cytotechnology."
A blood test that analyzes levels of amyloid proteins by highly sensitive mass spectrometry could help physicians establish that Alzheimer’s disease (AD) is likely not the cause of patients’ mild cognitive impairment, finds a new study published in Frontiers in Neurology by researchers from Quest Diagnostics, the University of Florida and Mount Sinai Medical Center in Miami Beach.
Precision medicine in rheumatoid arthritis expanded in a small but key measure late last year, when Quest Diagnostics and Scipher Medicine announced a partnership to provide RNA extraction and sequencing services for the latter’s PrismRA test.
Quest Diagnostics Health Trends topics are selected with expectations that reports may reveal important new novel public health insights. We collaborate with national academic experts and leaders in public health on many of our studies. To find impactful findings, this external input helps shape the objectives and study designs. Many of our studies have been highlighted by premier news outlets, nationally and regionally, and have been integrated into professional guidelines.
Quest Diagnostics on Tuesday announced a new tool available to dermatologists for making treatment decisions for patients with melanoma. The gene expression test, MelaNodal Predict, is based on technology developed by the oncology biotechnology company SkylineDx and researchers at Mayo Clinic.
Years of exposure to nonstick cookware, fast-food packaging, fire-fighting gear and water-resistant household products have resulted in increased levels of PFAS, also known as "forever chemicals," in practically every American's bloodstream. Quest Diagnostics announced Monday the first "consumer-initiated, physician-ordered blood-draw test for PFAS chemicals." The test, which you order online, will be available from most of Quest's approximately 2,100 diagnostic centers in the country and will include (if desired) a separate telephone consultation with a licensed physician to go over the results and ways to reduce the exposure risk.
Suhash Harwani, Ph.D, Senior Director of Science & Technology for Employer Solutions at Quest Diagnostics, shares drug positivity and testing options that employers should know about.
On Jan. 31, Fortune released its World's Most Admired Companies list, which included healthcare companies. The list, a partnership between Fortune and global management consulting firm Korn Ferry, follows an examination of about 1,500 candidates: the 1,000 largest U.S. companies ranked by revenue, along with non-U.S. companies in Fortune's Global 500 database that have revenues of $10 billion or more.
Just as users around the world are surely strapping on new Fitbits with an aim of tackling health-focused New Year’s resolutions, so too is Fitbit itself kicking off 2024 with its sights set on a new goal. The Google-owned fitness tracker maker is teaming up with Quest Diagnostics, according to a Wednesday release, to study how the combination of the two companies’ products could potentially help improve metabolic health, which is linked to conditions like diabetes, heart disease and stroke.
Quest Diagnostics has acquired select assets of outreach laboratory services in Pennsylvania and Ohio from Steward Health Care System, a large, private, and fully-integrated for-profit system based in Dallas. In addition, subject to transfer of the laboratory license, Quest has also acquired certain assets from the laboratory business serving Hawthorn Medical Associates in Dartmouth, MA.
Haystack Oncology said on Monday that it has struck a deal to investigate the use of its minimal residual disease (MRD) testing technology in non-small cell lung cancer (NSCLC) in collaboration with research organization Alliance Foundation Trials (AFT).
Quest Diagnostics and Scipher Medicine announced a collaboration designed to expand patient access to diagnostic services for rheumatoid arthritis. Under a multiyear collaboration, Quest will provide RNA extraction and next-generation sequencing services for Scipher’s PrismRA test, a blood-based molecular signature response classifier aimed at predicting a patient’s response to TNF inhibitor therapy.
Quest Diagnostics unveiled its new confirmatory testing service for novel psychoactive substances (NPS). The new panel, which tests for 88 compounds, covers a broad array of drug classes, such as designer opioids, designer benzodiazepines, designer stimulants, fentanyl analogs, synthetic cannabinoids, and other illicit additives.
On this episode I talked to Michael Racke, MD Medical Director of Neurology at Quest Diagnostics. Michael discusses promising advancements in our understanding and treatment of Alzheimer’s disease. He explains how imaging and biomarkers have allowed earlier and more accurate diagnosis, moving from just a clinical picture to actually visualizing amyloid plaques and tau tangles in the brain.
Quest Diagnostics said Thursday that its Haystack Oncology subsidiary has entered a collaboration agreement with Rutgers Cancer Institute of New Jersey for a study of early-stage triple-negative breast cancer patients. Researchers will use Haystack's MRD technology to help evaluate therapeutic response and collect molecular information on individuals undergoing treatment in the adjuvant setting with liposomal doxorubicin and carboplatin.
Secaucus-based Quest Diagnostics on Thursday said it was awarded a contract by the Centers for Disease Control and Prevention designed to assess the burden of hepatitis C virus in the U.S. The agreement marks a new phase of a decadelong collaboration between Quest and the CDC to improve hepatitis public health research based on insights from laboratory data.
Four local students from two academic institutions have been selected to participate in the American Heart Association’s Historically Black Colleges and Universities (HBCU) Scholars program, which is designed to help address racial disparity among medical students and physicians. According to the Association of American Medical Colleges, only eight percent of medical students and five percent of physicians are Black and African American. The program is funded by a grant provided by the Quest Diagnostics Foundation, which also supports the American Heart Association’s Hispanic Serving Institutes (HSI) Scholars Program.
Scipher Medicine and Quest Diagnostics have announced a multiyear collaboration to expand access to diagnostic services for patients with rheumatoid arthritis (RA).